Background: Using data from a national survey, this study aimed to address whether the current model for multidisciplinary team (MDT) working is appropriate for all tumour types. Results: One thousand one hundred and forty-one respondents from breast, gynaecological, colorectal, upper gastrointestinal, urological, head and neck, haematological and lung MDTs were included. One hundred and sixteen of 136 statements demonstrated consensus between respondents in different tumour types. There were no differences regarding the infrastructure for meetings and team governance. Significant consensus was seen for team characteristics, and respondents disagreed regarding certain aspects of meeting organisations and logistics, and patient-centred decision making. Haematology MDT members were outliers in relation to the clinical decision-making process, and lung MDT members disagreed with other tumour types regarding treating patients with advanced disease.
introduction
Multidisciplinary teams (MDTs) are becoming the model of care for patients with cancer in many countries across Europe [1, 2] , the USA [3] , Asia [4] , and Australia [5] . The introduction of MDTs in England was given impetus by the production of tumour-specific guidance (Improving Outcomes Guidance; IOG), which aimed to standardise and improve the outcomes of cancer care [6] . The rationale for MDT working is that as the management of patients with cancer becomes more complex, it is important to involve all key professional groups in making clinical decisions [7, 8] . MDTs, therefore, consist of surgeons, physicians, clinical and medical oncologists, radiologists, pathologists, and clinical nurse specialists (CNS) as a minimum [2] .
The benefits of MDT working are thought to include improved communication, coordination and decision making between health care professionals when weighing up treatment options. Indeed, multidisciplinary discussion can help health care professionals to tailor holistic treatment plans to patients' tumour type, biological markers as well as their co-morbidities and social circumstances [7] [8] [9] . However, research examining changes to clinical outcomes since the implementation of MDTs has led to inconclusive results since other factors including novel treatments, technology and service changes have evolved in parallel [10] [11] [12] . Evidence from the current process of 'peer review' in England along with previous research suggests that there is variability in the performance of MDTs [13] . In the UK, trials aiming to robustly evaluate the effectiveness of MDTs cannot be carried out any longer as MDT working is now ubiquitous having been mandated by the Department of Health for several years [2] .
Tackling variability in the performance of cancer MDTs requires agreement about type and extent of variation that is acceptable, and perhaps even desirable, and that which is likely to be related to effectiveness [11] . In the absence of empirical evidence about the characteristics of effective MDTs, the National Cancer Action Team recently conducted a national survey of MDT members' perceptions of MDT working [14] . Over 2000 MDT members responded to the survey, which has enabled a working definition of MDT effectiveness to be developed. Over 90% of respondents agreed that an effective MDT results in improved clinical decision making, more coordinated patient care, improvement to overall quality of care, more evidence-based treatment decisions, and improved treatment. In addition, there was strong agreement about the components of effective MDT working in relation to various domains of team working, including aspects of the structure, resources and process of decision making within cancer MDTs [14] . In the light of the findings of this national survey and with additional expert input, National Cancer Action Team (NCAT) published The Characteristics of an Effective MDT report [15] , which provides a working definition that is being used as a springboard for the assessment and development of MDTs.
The aim of the 'Characteristics' report is to describe the characteristics, which enable effective MDT working. While there is some room for flexibility and interpretation by locality and cancer type for some of the characteristics in this document, the underlying assumption is that the basic model for MDT working is appropriate for all tumour types [15] . To date, however, this assumption has not been validated. Therefore, the aim of the study reported here was to empirically test this assumption regarding MDT working using data from the NCAT national survey. Successful validation of the MDT working model proposed in the 'Characteristics' report would mean that a generic national assessment tool and development process is applicable across all tumour types. Adopting a standardised and broadly applicable MDT development programme will give MDT members across the UK a mandate with which they can improve their own teams, which in turn will ensure that patients receive care that conforms to the best standards of practice.
The results from the 2009 NCAT survey were summarised in a report where descriptive comparisons were made of perceptions of MDT working across professional groups and tumour types but no statistical techniques were applied [14] . In this study, appropriate statistical techniques were applied in order to:
Systematically analyse responses relating to the components of effective MDT working Identify areas of consensus and difference in opinion/ perceptions between MDT members from different tumour types methods the 2009 NCAT national survey
The survey aimed to investigate MDT members' perceptions about effective MDT working [14] . It was designed with input from a steering group consisting of 32 cancer professionals, including representatives from all core disciplines in cancer MDTs. Surveys were completed online between 30 January and 16 March 2009. The survey contained 131 statements which were rated on 1-4 Likert scales (1 = strongly disagree, 4 = strongly agree), along with five additional multiple-choice questions, all of which are included in the current analysis. In addition, there was a background section to collect information about respondents' demographics and current working practices and also some free text questions-these are not included in this paper. The domains of team working covered by the survey and analysed here are depicted in Figure 1 .
Survey participants were recruited using a snowball sampling method via cancer networks, cancer service managers, the MDT coordinators forum and the Network Development Programme forum for Informatics. Participants were sent an introductory email with the web address of the survey and were encouraged to circulate the details broadly among MDT members. A link to the survey was also provided on the National Cancer Intelligence Network website. Anonymity was assured and informed consent implied by completion of the survey.
participants
Due to the focus on tumour type differences, only respondents who were core or extended members of an MDT and who worked in a single tumour type were included in analysis. The survey only enabled an 'overall' opinion rather than permitting respondents to give different responses for different teams/tumour types. Therefore, the responses of those who work in more than one tumour type would be averaged across the different teams they work in, thus artificially reducing any difference that might occur between tumour types. In addition, members of tumour types with <100 responses were excluded to ensure all subgroup analyses were carried out on a statistically robust sample size. Included tumour types were breast, gynaecological, colorectal, upper gastrointestinal, urological, head and neck, haematological and lung.
analysis Following the NCAT report authors' recommendations [14] , which were intended to render the analysis most meaningful and also to simplify a very extensive dataset, responses were aggregated into agree/disagree categories (scale ratings 3 or 4 = agree; scale rating 1 or 2 = disagree). Three levels of analysis were undertaken. Firstly, statements for which the difference between the tumour group with the highest and the lowest percentage agreement was <20% were treated as consensus. In these cases, no further analysis was undertaken. Secondly, where the difference between the tumour group with the highest and the lowest percentage agreement was ‡20%, the nonparametric Kruskal-Wallis test was applied to responses to each statement in order to explore differences by tumour type. For each statement, a non-significant test result would indicate that responses were similar across tumour types, implying consensus. In these cases, no further analysis was undertaken. A significant Kruskal-Wallis test would indicate differences in perceptions across tumour types, which were submitted to a third line of analysis. For the third analysis, pair-wise comparisons were undertaken between the different tumour types using the nonparametric Mann-Whitney U-test. As in the previous analysis, non-significant Mann-Whitney results between any two tumour types on pair-wise comparison would indicate consensus between the pair, whereas significant results would indicate differences in perception/opinion original articles Annals of Oncology between specific tumour types. Bonferroni correction with nominal P <0.05 was used for multiple comparisons to minimise statistical bias (type I error). All statistical analyses were performed using SPSS version 17Á0 (SPSS Inc., Chicago, IL).
results respondents
Of 2054 respondents to the survey, 1141 met the criteria for inclusion in this analysis (were members of MDTs that only covered one tumour type and there were at least 100 respondents in the tumour type). These included members of eight of the most common tumour types: breast, colorectal, lung, gynaecological, head and neck, upper gastrointestinal, urological, and haematological cancers, with the exclusion of skin, brain and CNS, sarcoma and children and young people due to sample size of <100. The professional groups of respondents within each tumour type are shown in Table 1 .
consensus and differences across tumour types
The responses to 116 of the total 136 statements were similar across tumour types (no significant difference across tumour types, as assessed by Kruskal-Wallis tests and Mann-Whitney U-test). The remaining 20 statements showed significant differences between the responses of different tumour types ( Table 2) .
There were no differences in opinions between MDT members from the different tumour types regarding aspects of team working that related to the infrastructure for meetings and team governance (Table 3 ). Significant agreement (i.e. no more than 20% difference between the highest and lowest percentage agreement across tumour types) was obtained for these domains.
Similarly, significant consensus was obtained for most of the survey statements in the other domains, including characteristics of the team, MDT meeting organisation and logistics, and patient-centred clinical decision making (Table 4) . Within these three domains, however, there were also significant differences between tumour types for some statements-these are reported in detail in Table 5 .
Regarding tumour types, haematology participants were consistently different from other tumours (involved in 8 of the 20 non-consensual statements), followed by lung participants (involved in 6 of the 20). Other tumour types showed fewer discrepancies from the general consensus. Regarding domains, tumour types disagreed in relation to circulating case summaries before the meeting (breast, colorectal and lung did not agree) and not allowing late additions to the agenda (colorectal and lung did not agree). Both of these are aspects of meeting organisations and logistics. Moreover, disagreement was evident on whether a patient should be discussed in an MDT if no one is present who has seen the patient (gynaecological and upper gastrointestinal did not agree with this), which is an aspect of patient-centred decision-making care. Within the same domain, haematology was an outlier in relation to several statements about the process of clinical decision making in MDTs-including whether MDT discussion improves timeliness of care, patient choice, patient involvement, patient staging, and survival rates. Lung participants also contributed to three significant disagreements within this domain that related to palliative care processes, discussion of patients with recurrences, and oncologists making treatment decisions without MDT support for some patients.
discussion
This study aimed to systematically assess whether there exist tumour-based differences in definition of effectiveness of MDT working. Consensus between team members from different tumour types was very high-the majority (116/136) statements were answered similarly regardless of tumour specialty of the respondent. The differences of opinion we have revealed related to preparation for, and organisation of MDT meetings, case selection and the clinical decision-making process. This study offers statistical evidence that MDT members from different tumour types across the UK are in reasonable agreement about what constitutes effective MDT working. These results provide a robust confirmation of the high level of consensus that has led to the production of The Characteristics of an Effective MDT [15] -therefore confirming that this report can be used as a benchmark against which teams from different tumour types can assess their performance. Although the areas of difference between tumour types are few, they do suggest that in areas of case selection, preparation for/organisation of meetings, and clinical decision making, the recommendations/guidelines for MDT working should be sensitive to tumour type (Figure 2 ). In particular, haematology MDTs seem to be outliers in certain areas. Services for patients with haematological malignancies, as is acknowledged in the IOG, have certain distinctive features [16] . Although the management of haematological malignancies also involves a range of clinical and laboratory professionals, the processes of diagnosis and subsequent clinical management are dominated by clinical haematologists. Implementation of MDT working in haematology may need to be adjusted accordingly to ensure that the mode of MDT working adopted is beneficial to patients and health care professionals. Similarly, the requirement of different tumour types regarding patients with advanced or recurrent disease and the need for re-presentation at the MDT or the involvement of palliative care services may need to be agreed individually to reflect the differing workload and clinical characteristics of different tumour types [16] .
The results of this analysis should be interpreted against certain limitations. The sampling method used for the survey involved snowballing so it is not possible to estimate the representativeness of responses with any confidence. However, the sample adequately represents respondents across core MDT members, common tumour types and a wide range of geographical locations throughout England. Team members were only able to give one response per statement, which meant that respondents who worked in multiple teams across different tumour types were not able report opinions relating to different teams. Our analysis had to exclude such team members and include only those who worked in one tumour type so that only data relating to specific tumour types was included. This imposes an inevitable bias on the sample as MDT members who commonly work across multiple tumour types including oncologists, radiologists and histopathologists are underrepresented in this study. Consequently, the largest professional groups in this analysis are nurses, surgeons and MDT coordinators, and as such, their views may be most strongly represented in the results. Future research should elicit the opinions of these professional groups to validate the results of this study. Moreover, professionals who work in more than one tumour type may provide interesting insights into the differences identified in this study by virtue of working in different and possibly contrasting teams [14] . In addition, further work should be undertaken to investigate the views of health care professionals working in MDTs not included in this analysis, in particular members of MDTs working with children and young people, who may need to work in a different way from those working with adult patients.
The measurement of the effectiveness of MDTs remains to be defined [9] [10] [11] [12] . Although traditional measures of outcome, such as survival data, give a robust account of whether an intervention is effective or not, for a complex care pathway of which the MDT meeting us but one part, it may not be possible to attribute changes in patient outcomes to the effect of the MDT [7] .
Ultimately, clinical outcomes should be included when assessing MDT performance, but other short-term outcome and potentially also process measures (such as time from first referral to diagnosis, time from diagnosis to the first treatment, and costs reductions), should also be developed. There is evidence that the ability of an MDT to reach a decision on first-case presentation and ability of MDT decisions to be implemented appear to be a useful marker of the performance of the MDT [9] . Moreover, outcomes such as patient satisfaction and health care professional satisfaction are also increasingly seen as important measures of the effectiveness of health care [17, 18] .
The findings reported here may have a role in improving the current 'peer review' process of MDT assessment. There is currently a growing evidence base on valid, reliable and structured assessment tools for applications across a range of health care specialties [19] [20] [21] . Such tools have been shown to improve team working and are well received by the teams who use them [22] . The areas of team working and clinical decision making as set out in the 'Characteristics' report are currently not covered by the peer review process [2, 13, 15] . These are also the areas in which differences between tumour types became apparent in the present study. Additional assessment tools and/or processes, tailored to individual tumour types as revealed here, may therefore be required to capture these 'nontechnical' aspects of cancer teams' performance. To this end, our research group has recently developed such tools for application to cancer MDTs and showed that they are valid, feasible and based on current best evidence [23] [24] [25] . In addition, NCAT is developing an MDT self-assessment programme known as MDT-FIT ('Feedback for Improving Team-working'), which is aimed at supporting teams to selfevaluate their performance and receive feedback and support for improvement. With continued development, such programmes may augment current assessment methods to facilitate team working and team functioning in cancer MDTs, thereby enhancing patient safety and care.
conclusions
We report a rigorous analysis of responses to a recent NCAT national survey of MDT members' views of the characteristics of effective MDT functioning. The current analysis reveals numerous areas of consensus across different tumour types, while also identifying some areas that may require a more tailored approach. In particular, haematology MDTs may not benefit from a generic model of MDT working, though members from all common tumour types expressed variation in some areas of team working and clinical decision making. As the prominence of MDT working grows, it is important that policymakers remain sensitive to the needs of health care teams working in individual tumour types.
